---
title: "Oncocyte prices $29.1M equity offering"
date: "2025-02-10 16:50:30"
summary: "Oncocyte (NASDAQ:OCX) said on Monday that it has entered into a securities purchase agreement with existing investors for a registered direct offering and concurrent private placement. The company’s five largest shareholders, including Bio-Rad Laboratories (BIO), a key strategic partner of the company, led the funding round. The round is expected..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Oncocyte (NASDAQ:[OCX](https://seekingalpha.com/symbol/OCX "OncoCyte Corporation")) said on Monday that it has [entered into a securities purchase agreement](https://seekingalpha.com/pr/19996652-oncocyte-prices-29_1-million-equity-offering) with existing investors for a registered direct offering and concurrent private placement.
* The company’s five largest shareholders, including Bio-Rad Laboratories ([BIO](https://seekingalpha.com/symbol/BIO "Bio-Rad Laboratories, Inc.")), a key strategic partner of the company, led the funding round.
* The round is expected to result in gross cash proceeds to the company totaling $29.1M, priced at $2.05 per share. Two members of the company’s management team also participated in the private placement.
* In addition to its equity investment, Bio-Rad has pledged to provide valuable financial support for the upcoming clinical trial and further commercialization assistance.
* Combined with Oncocyte’s current cash on hand, the offering proceeds are expected to fully fund the development of the company's FDA In-Vitro Diagnostic transplant assay program.
* FDA clearance of Oncocyte’s proprietary transplant assay is a key milestone to driving self-sustaining revenue.
* Oncocyte ([OCX](https://seekingalpha.com/symbol/OCX "OncoCyte Corporation")) shares were up 6.97% in pre-market trading.

[seekalpha](https://seekingalpha.com/news/4405581-oncocyte-prices-291m-equity-offering)
